Zovaglutide | GLP-1 Receptor Agonist

Description

Product Description

Zovaglutide (CAS No. 3013543-64-8) is a synthetic peptide that functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 receptors are a critical component in glucose homeostasis, insulin secretion, and appetite regulation. By binding selectively to GLP-1 receptors, Zovaglutide mimics the action of endogenous GLP-1, leading to enhanced insulin secretion in a glucose-dependent manner and suppression of glucagon release.

This pharmacological profile makes Zovaglutide a valuable molecule in diabetes research. It allows researchers to study the effects of GLP-1 receptor activation on pancreatic β-cells, glucose metabolism, and weight regulation. Additionally, it has potential applications in investigating cardiovascular and neuroprotective effects associated with GLP-1 receptor signaling.

Zovaglutide’s long-acting properties provide a more sustained pharmacokinetic profile compared to native GLP-1, which has a very short half-life due to rapid enzymatic degradation. This makes it particularly suitable for in vitro and in vivo experiments requiring prolonged receptor activation. Researchers can use Zovaglutide in animal models of type 2 diabetes, obesity, and metabolic syndrome to better understand disease mechanisms and evaluate therapeutic interventions.

Key Highlights:

• Potent GLP-1 receptor agonist

• Supports glucose-dependent insulin secretion studies

• Long-acting pharmacokinetics for sustained research applications

• Applicable in metabolic, cardiovascular, and neuroprotective research

Zovaglutide is supplied as a highly pure, laboratory-grade peptide. Proper storage and handling are essential to maintain stability and bioactivity. Typically, peptides like Zovaglutide are stored at -20°C or lower, with minimal freeze-thaw cycles, and reconstituted in appropriate solvents before use in experimental protocols.

Product Specifications

Mechanism

Zovaglutide acts as a GLP-1 receptor agonist. Upon binding to the GLP-1 receptor on pancreatic β-cells, it activates adenylate cyclase, leading to increased cyclic AMP (cAMP) levels. This triggers insulin secretion in a glucose-dependent manner. In addition, it suppresses glucagon secretion from α-cells and slows gastric emptying, contributing to reduced postprandial glucose levels. Central nervous system effects include appetite suppression, potentially aiding in weight regulation.

Side Effects (Research Context)

• In preclinical models, high doses may cause transient gastrointestinal disturbances.

• May induce hypoglycemia if combined with other insulinotropic agents.

• Potential mild injection site reactions in animal models.

• Not intended for human therapeutic use outside research settings.

Disclaimer

Zovaglutide is for laboratory research purposes only. It is not intended for human consumption or clinical use. Researchers must follow all local and institutional guidelines for handling peptides and hazardous materials. The information provided is for scientific reference and experimental planning only.

Keywords

Zovaglutide, GLP-1 receptor agonist, diabetes research peptide, type 2 diabetes study, metabolic research, CAS 3013543-64-8, GLP-1 peptide, insulin secretion study, antidiabetic research peptide, preclinical diabetes model

Shipping Guarantee

• Dispatched with temperature-controlled packaging.

• Shipped via insured carriers to ensure product integrity.

• Worldwide shipping with full tracking available.

Purchase Guarantee

• 100% laboratory-grade purity guarantee.

• Secure payment and verified shipping partners.

• Customer support available for handling and storage guidance.